IL279843A - פפטידים מוגבלים ל-a 03 לשימוש באימונותראפיה כנגד סרטן ושיטות קשורות - Google Patents

פפטידים מוגבלים ל-a 03 לשימוש באימונותראפיה כנגד סרטן ושיטות קשורות

Info

Publication number
IL279843A
IL279843A IL279843A IL27984320A IL279843A IL 279843 A IL279843 A IL 279843A IL 279843 A IL279843 A IL 279843A IL 27984320 A IL27984320 A IL 27984320A IL 279843 A IL279843 A IL 279843A
Authority
IL
Israel
Prior art keywords
related methods
cancer immunotherapy
restricted peptides
peptides
restricted
Prior art date
Application number
IL279843A
Other languages
English (en)
Inventor
Schoor Oliver
Singh Harpreet
Schuster Heiko
Kowalewski Daniel
Song Colette
fritsche Jens
Weinschenk Toni
Backert Linus
Original Assignee
Immatics Biotechnologies Gmbh
Schoor Oliver
Singh Harpreet
Schuster Heiko
Kowalewski Daniel
Song Colette
fritsche Jens
Weinschenk Toni
Backert Linus
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102018115865.3A external-priority patent/DE102018115865A1/de
Application filed by Immatics Biotechnologies Gmbh, Schoor Oliver, Singh Harpreet, Schuster Heiko, Kowalewski Daniel, Song Colette, fritsche Jens, Weinschenk Toni, Backert Linus filed Critical Immatics Biotechnologies Gmbh
Publication of IL279843A publication Critical patent/IL279843A/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL279843A 2018-06-29 2020-12-29 פפטידים מוגבלים ל-a 03 לשימוש באימונותראפיה כנגד סרטן ושיטות קשורות IL279843A (he)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862692348P 2018-06-29 2018-06-29
DE102018115865.3A DE102018115865A1 (de) 2018-06-29 2018-06-29 A*03-restringierte Peptide zur Verwendung in der Immuntherapie gegen Krebs und verwandte Verfahren
DE102018116584 2018-07-09
US16/030,725 US10925947B2 (en) 2018-06-29 2018-07-09 A*03 restricted peptides for use in immunotherapy against cancers and related methods
PCT/EP2019/066115 WO2020002063A1 (en) 2018-06-29 2019-06-19 A*03 restricted peptides for use in immunotherapy against cancers and related methods

Publications (1)

Publication Number Publication Date
IL279843A true IL279843A (he) 2021-03-01

Family

ID=67070807

Family Applications (1)

Application Number Title Priority Date Filing Date
IL279843A IL279843A (he) 2018-06-29 2020-12-29 פפטידים מוגבלים ל-a 03 לשימוש באימונותראפיה כנגד סרטן ושיטות קשורות

Country Status (19)

Country Link
US (12) US10925947B2 (he)
EP (1) EP3813873A1 (he)
JP (2) JP7579145B2 (he)
KR (1) KR20210025534A (he)
CN (2) CN112399853A (he)
AU (1) AU2019294731A1 (he)
BR (1) BR112020022250A2 (he)
CA (1) CA3097698A1 (he)
CL (4) CL2020003371A1 (he)
CO (1) CO2020013659A2 (he)
CR (1) CR20200632A (he)
IL (1) IL279843A (he)
MA (1) MA53004A (he)
MX (1) MX2020012257A (he)
PE (1) PE20211499A1 (he)
PH (1) PH12020552013A1 (he)
SG (1) SG11202009659XA (he)
TW (1) TW202019462A (he)
WO (1) WO2020002063A1 (he)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018251839B2 (en) * 2017-04-10 2022-06-30 Immatics Biotechnologies Gmbh Peptides and combination thereof for use in the immunotherapy against cancers
KR20220167288A (ko) * 2020-04-14 2022-12-20 유니버시떼 드 몬트리얼 급성 골수성 백혈병(aml)에 대한 신규한 종양-특이적 항원 및 이의 용도
KR102620744B1 (ko) 2021-08-18 2024-01-02 주식회사 케이티앤지 니코틴 인헤일러
WO2024077601A1 (en) * 2022-10-14 2024-04-18 Guangdong Tcrcure Biopharma Technology Co., Ltd. Peptide vaccines against glioma and uses thereof
WO2025040598A2 (en) * 2023-08-18 2025-02-27 Immatics Biotechnologies Gmbh Peptides displayed by mhc for use in immunotherapy against different types of cancer
CN119530167A (zh) * 2024-08-30 2025-02-28 江苏亲科生物研究中心有限公司 Scgb1d4单克隆抗体及其试剂盒的制备方法和用途

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
IE53176B1 (en) 1978-12-22 1988-08-17 Biogen Nv Recombinant dna molecules and their method of production
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
US9340577B2 (en) 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
ATE183513T1 (de) 1993-06-03 1999-09-15 Therapeutic Antibodies Inc Herstellung von antikörperfragmenten
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
US5807978A (en) 1995-06-07 1998-09-15 Kokolus; William J. Immunogenic peptides of prostate specific antigen
ES2203782T3 (es) 1996-01-17 2004-04-16 Imperial College Innovations Limited Inmunoterapia que utiliza linfocitos t citotoxicos (ctl).
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
AUPO500997A0 (en) * 1997-02-07 1997-03-06 Macquarie Research Limited Diagnosis of disease using tears
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US20070020327A1 (en) * 1998-11-10 2007-01-25 John Fikes Inducing cellular immune responses to prostate cancer antigens using peptide and nucleic acid compositions
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
CA2404489A1 (en) 2000-03-27 2001-10-04 Technion Research And Development Foundation Ltd. Single chain class i major histo-compatibility complexes, constructs encoding same and methods of generating same
US20030144474A1 (en) 2000-06-05 2003-07-31 Sunol Molecular Corporation T cell receptor fusions and conjugates and methods of use thereof
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
US20030223994A1 (en) 2002-02-20 2003-12-04 Hoogenboom Henricus Renerus Jacobus Mattheus MHC-peptide complex binding ligands
NZ539225A (en) 2002-10-09 2006-09-29 Avidex Ltd Single chain recombinant T cell receptors
ES2327229T3 (es) 2002-11-09 2009-10-27 Immunocore Ltd. Presentacion del receptor de linfocitos t.
EP1583548A4 (en) * 2002-12-10 2007-10-17 Epimmune Inc PEPTIDES DIRECTED AGAINST ANTIGENS ASSOCIATED WITH HLA-A1, A2 -A3, -A24, -B7, AND -B44 TUMORS AND COMPOSITIONS
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
ATE461215T1 (de) 2005-09-05 2010-04-15 Immatics Biotechnologies Gmbh Tumor-assoziierte peptide, welche an unterschiedliche menschliche leukozytenantigene der klasse ii binden
CN106220721B (zh) * 2007-03-26 2020-04-07 莱顿大学医学中心附属莱顿教学医院 Prame衍生的肽以及包括该肽的免疫原组合物
US7867483B2 (en) * 2007-10-18 2011-01-11 Bn Immunotherapeutics, Inc. Use of MVA to treat prostate cancer
US20090263574A1 (en) 2008-04-21 2009-10-22 Quinn Daniel E Method of restoring an article
US9840695B2 (en) 2009-04-28 2017-12-12 Agriculture Victoria Services Pty Ltd Plant technology
US9023802B2 (en) 2009-12-14 2015-05-05 Immatics Biotechnologies Gmbh HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
EP2632955A1 (en) 2010-10-26 2013-09-04 Technion Research & Development Foundation Ltd. Antibodies which bind soluble t-cell receptor ligands
WO2013057586A1 (en) 2011-10-19 2013-04-25 Oslo Universitetssykehus Hf Compositions and methods for producing soluble t - cell receptors
WO2014071978A1 (en) 2012-11-08 2014-05-15 Roche Diagnostics Gmbh Nucleic acids encoding chimeric polypeptides for library screening
EP2808392A1 (en) 2013-05-28 2014-12-03 Rheinische Friedrich-Wilhelms-Universität Bonn Aptamers and use of the aptamers in the diagnosis and treatment of cancer
TWI714869B (zh) * 2013-08-05 2021-01-01 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
GB201411037D0 (en) * 2014-06-20 2014-08-06 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL)
MA41217A (fr) * 2014-12-19 2017-10-24 Advaxis Inc Polythérapies ayant des souches de listeria recombinées
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
JP7236216B2 (ja) * 2015-04-23 2023-03-09 ナントミクス，エルエルシー がんのネオエピトープ
GB201513921D0 (en) 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
GB201517538D0 (en) 2015-10-05 2015-11-18 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
WO2017089786A1 (en) 2015-11-23 2017-06-01 Immunocore Limited Peptides
GB201520583D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
US10946106B2 (en) 2015-11-30 2021-03-16 The Regents Of The University Of California Tumor-specific payload delivery and immune activation using a human antibody targeting a highly specific tumor cell surface antigen
BR112019028280A2 (pt) 2017-07-04 2020-07-14 Curevac Ag moléculas de ácido nucleico
JP2021508475A (ja) * 2017-12-28 2021-03-11 グリットストーン オンコロジー インコーポレイテッド 共有抗原を標的とする抗原結合タンパク質

Also Published As

Publication number Publication date
SG11202009659XA (en) 2021-01-28
US10828357B2 (en) 2020-11-10
CA3097698A1 (en) 2020-01-02
CL2020003371A1 (es) 2021-05-07
US20210138052A1 (en) 2021-05-13
JP2025013943A (ja) 2025-01-28
US11872270B2 (en) 2024-01-16
JP2021528046A (ja) 2021-10-21
US11833193B2 (en) 2023-12-05
US20210330771A1 (en) 2021-10-28
KR20210025534A (ko) 2021-03-09
US20230226162A1 (en) 2023-07-20
AU2019294731A1 (en) 2020-10-29
US20210330772A1 (en) 2021-10-28
US10946081B2 (en) 2021-03-16
CN113444148A (zh) 2021-09-28
CL2022003380A1 (es) 2023-06-02
US20210128707A1 (en) 2021-05-06
CL2022003381A1 (es) 2023-06-02
US11576955B2 (en) 2023-02-14
US12076379B2 (en) 2024-09-03
CO2020013659A2 (es) 2020-11-10
TW202019462A (zh) 2020-06-01
JP7579145B2 (ja) 2024-11-07
CN112399853A (zh) 2021-02-23
US20220370583A1 (en) 2022-11-24
EP3813873A1 (en) 2021-05-05
US10925947B2 (en) 2021-02-23
US20200289632A1 (en) 2020-09-17
US10869917B2 (en) 2020-12-22
CR20200632A (es) 2021-01-25
PH12020552013A1 (en) 2021-06-28
US11554164B2 (en) 2023-01-17
US11058755B2 (en) 2021-07-13
US20200000897A1 (en) 2020-01-02
US20210128708A1 (en) 2021-05-06
MX2020012257A (es) 2021-03-25
US11246917B2 (en) 2022-02-15
PE20211499A1 (es) 2021-08-11
MA53004A (fr) 2021-05-26
WO2020002063A1 (en) 2020-01-02
BR112020022250A2 (pt) 2021-02-23
CL2022003382A1 (es) 2023-06-02
US20200000895A1 (en) 2020-01-02
US20220362364A1 (en) 2022-11-17
US20200323970A1 (en) 2020-10-15

Similar Documents

Publication Publication Date Title
IL279843A (he) פפטידים מוגבלים ל-a 03 לשימוש באימונותראפיה כנגד סרטן ושיטות קשורות
IL282225A (he) תכשירים ושיטות לאימונותרפיה
IL269741A (he) פפטידים וצירופים שלהם לשימוש באימונותרפיה נגד סרטן
IL280544A (he) אימונותראפיה עם פפטידים חתוכים על b 07 ושילובים שלהם כנגד סרטן ושיטות קשורות
ZA202006904B (en) Anti-il-4r antibody and use thereof
HUE053657T2 (hu) Peptidek és peptidkombinációk a prosztatarák és más ráktípusok elleni immunterápiában történõ használatra
SG11202100746WA (en) Anti-tigit antibody and use thereof
IL259304A (he) פפטידים חדשים ושילוב של פפטידים לשימוש באימונותרפיה נגד cll וסוגים אחרים של סרטן
ZA202006066B (en) Anti-hla-g antibodies and use thereof
IL280317A (he) נוגדנים כנגד avb8 ותכשירים ושימוש בהם
IL261786A (he) פפטידים ושילוב של פפטידים לשימוש באימונותרפיה כנגד סוגים של סרטן
IL281605A (he) פפטידים מוגבלי b 44 לשימוש באימונותראפיה לטיפול בסרטן ושיטות נגזרות
IL256303A (he) פפטידים חדשים ושילוב של פפטידים לשימוש באינוניתרפיה נגד סרטן הושט וסוגי סרטן אחרים
IL257577A (he) פפטידים חדשים ושילוב בין פפטידים ותמיכות לשימוש בטיפול אימונותרפי בסוגים שונים של סרטן
IL281596A (he) אימונותראפיה עם פפטידים מוגבלי a 01 ושילובים שלהם כנגד סרטן ושיטות נגזרות
IL283644A (he) תכשירים ושיטות לאימונותרפיה
IL283942A (he) טובוליסינים וצימוד חלבון-טובוליסין
IL280631A (he) חלבון הקשור ל-קריספר חדש ושימוש בו
IL269813A (he) פפטידים ושילובים שלהם לשימוש באימונותרפיה נגד לוקמיה וסוגי סרטן אחרים
IL258609A (he) פפטידים חדשים ושילוב של פפטידים לשימוש באימונותרפיה נגד מספר סוגים של סרטן
IL289205A (he) אנטיגנים לסרטן חדשים ושיטות
IL282478A (he) חומרים ושיטות לטיפול בסרטן
SG11202009442YA (en) Peptides for use in immunotherapy against cancers
SG11202006669RA (en) Peptides and uses thereof
IL292872A (he) תכשירים ושיטות לאימונותרפיה